Rate My Professor Steven Bollipo

Dr. Steven Bollipo is a Conjoint Associate Professor in the School of Medicine and Public Health at the University of Newcastle, Australia, within the Medicine faculty. He also serves as Clinical Senior Lecturer in Medicine at the university. In clinical practice, he is Head of the Department of Gastroenterology at John Hunter Hospital, Newcastle, and has held the role of Director of Gastroenterology and Endoscopy there. Bollipo possesses the qualifications MBBS and FRACP. Affiliated with the Hunter Medical Research Institute (HMRI), his work integrates clinical care, medical education, and research in gastroenterology and hepatology.

Bollipo's academic interests center on gastroenterology and hepatology, with emphasis on endoscopy training, quality improvement through initiatives like #Scopemanship, liver diseases including hepatitis B, cirrhosis, hepatocellular carcinoma (HCC), and non-alcoholic fatty liver disease (NAFLD, renamed MAFLD). He investigates the microbiome's role in liver cancer pathogenesis and addresses impacts of COVID-19 on endoscopy and liver disease management. He has produced 83 publications, cited over 1,209 times. Key publications include: “What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’” (2020, 389 citations); “Overview of guidance for endoscopy during the coronavirus disease 2019 pandemic” (2020, 199 citations); “Impact of COVID-19 on endoscopy trainees: an international survey” (2020, 112 citations); “Narrative review: Risk of eating disorders and nutritional deficiencies with dietary therapies for irritable bowel syndrome” (2022, 52 citations); “One world, one pandemic, many guidelines: management of liver diseases during COVID-19” (2020, 48 citations). Recent works cover HCC treatment outcomes, such as “Early-Stage Australian HCC Patients Treated at Tertiary Centres Show Comparable Survival Across Metropolitan and Non-Metropolitan Residency” (2026), “Initial Trans-Arterial Chemo-Embolisation (TACE) Is Associated with Similar Survival Outcomes as Compared to Upfront Percutaneous Ablation” (2024), and “Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC” (2023). Bollipo engages the academic community via social media (@stevenbollipo) and as a member of the European Society of Gastrointestinal Endoscopy (ESGE) social media working group, promoting discourse in #gitwitter and #livertwitter.